Intervention Reduces Use of Systemic Therapy at End of Life in Cancer Patients
An intervention can increase serious illness conversations and reduce the use of systemic therapy at the end of life in patients with cancer.
All articles by Leah Lawrence
Childhood, Adolescent Cancers Linked to Higher Risk of Major Psychiatric Disorders
Compared with the general population, survivors of childhood and adolescent cancers have an increased risk of 6 major psychiatric disorders.
Deep Learning Model Predicts Lung Cancer Risk Using Single CT Scan
A deep learning model called Sybil can predict a person’s risk of lung cancer using a single low-dose CT scan, a study suggests.
Survey Reveals Confusion About Causes of Cancer, Especially Among Anti-Vaxxers and Conspiracy Theorists
Awareness of factors that cause cancer is especially poor among people who reject vaccines, prefer alternative medicine, or believe conspiracy theories.
Fewer Serious Adverse Events Reported in Cancer Trials During COVID-19 Pandemic
Serious adverse events were reported less frequently among patients enrolled in cancer trials during the first 2 years of the COVID-19 pandemic than among patients enrolled prior to the pandemic.
Trial Raises Questions About Effectiveness of Colonoscopy for Colorectal Cancer Screening
Screening colonoscopy may provide a small reduction in the risk of colorectal cancer and no reduction in the risk of death, a study suggests.
Test May Improve Early Detection of Pancreatic Cancer
The gene sequencing panel PancreaSeq can accurately classify pancreatic cysts as benign or potentially cancerous, according to researchers.
NCCN Updates Recommendations for COVID-19 Vaccination
NCCN has updated its recommendations on COVID-19 vaccination to include advice about bivalent vaccines, vaccinating immunocompromised children, and more.
Breast Cancer Updates From ESMO 2022
Results from the TROPiCS-02, DATA, GIM2, and METEORA-II trials may help inform the treatment of breast cancer.
No Survival Benefit With T-VEC in Advanced Melanoma
Adding T-VEC to pembrolizumab does not improve survival in patients with advanced melanoma, a phase 3 study suggests.
- Loading...
Loading...
Next post in Oncology
Loading... 
Loading...